Nymox Pharmaceutical Corp. Daily Stock Analysis

Daily Stock Analysis, NYMX, Nymox Pharmaceutical Corp, priceseries

Nymox Pharmaceutical Corp. Daily Stock Analysis
Stock Information
Open
2.10
Close
1.83
High
2.10
Low
1.80
Previous Close
2.00
Daily Price Gain
-0.17
YTD High
2.10
YTD High Date
Mar 7, 2022
YTD Low
1.18
YTD Low Date
Jan 3, 2022
YTD Price Change
0.49
YTD Gain
36.57%
52 Week High
2.87
52 Week High Date
Apr 27, 2021
52 Week Low
0.94
52 Week Low Date
Dec 30, 2021
52 Week Price Change
-0.67
52 Week Gain
-26.80%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 1. 2017
3.04
Feb 10. 2017
3.35
7 Trading Days
10.04%
Link
LONG
Mar 1. 2018
3.30
Mar 9. 2018
3.47
6 Trading Days
5.02%
Link
LONG
Mar 16. 2018
3.75
Apr 3. 2018
3.99
11 Trading Days
6.38%
Link
LONG
Jan 2. 2019
1.57
Jan 29. 2019
2.11
18 Trading Days
34.10%
Link
LONG
Feb 6. 2019
2.20
Feb 20. 2019
2.36
9 Trading Days
7.08%
Link
LONG
Jun 13. 2019
1.53
Jun 25. 2019
1.71
8 Trading Days
11.51%
Link
LONG
Sep 5. 2019
1.72
Sep 24. 2019
1.90
13 Trading Days
10.60%
Link
LONG
Dec 9. 2019
1.96
Dec 18. 2019
2.10
7 Trading Days
7.14%
Link
LONG
Jan 2. 2020
2.35
Jan 23. 2020
3.00
14 Trading Days
27.64%
Link
LONG
Jan 28. 2020
3.06
Feb 6. 2020
3.30
7 Trading Days
7.72%
Link
LONG
Feb 20. 2020
3.22
Feb 24. 2020
3.43
2 Trading Days
6.46%
Link
LONG
Apr 17. 2020
2.35
May 14. 2020
2.98
19 Trading Days
26.73%
Link
LONG
Dec 16. 2020
2.25
Dec 22. 2020
2.40
4 Trading Days
6.44%
Link
LONG
Aug 13. 2021
1.62
Sep 7. 2021
2.12
16 Trading Days
30.74%
Link
Company Information
Stock Symbol
NYMX
Exchange
NasdaqCM
Company URL
http://www.nymox.com
Company Phone
1-800-936-9669
CEO
Paul Averback
Headquarters
Quebec
Business Address
9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT, QUEBEC CANADA, CANADA H4M 2V2
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0001018735
About

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which specializes in the research and development of products for the aging population. The company markets NicAlertTM and TobacAlertTM, tests that use urine or saliva to detect use of tobacco products. It develops NX-1207, a novel treatment for benign prostatic hyperplasia, which is in Phase 3 clinical trials. It also has pipeline drug candidates aimed at the causes of Alzheimer's disease and new treatments of bacterial infections in humans. Nymox Pharmaceutical was founded by Paul Averback on May 30, 1995 and is headquartered in Saint-Laurent, Canada.

Description

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, The Bahamas.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading